- 5-fluorouracil (f-FU); ECF: epirubicin (Ellence®), cisplatin, and 5-FU; DCF: docetaxel (Taxotere®), cisplatin, and 5-FU; cisplatin with capecitabine; oxaliplatin and either 5-FU or capecitabine; and irinotecan.
- 22. The reagent of any one of claims 18-21, wherein the micelle comprises trastuzumab or ramucirumab.
- 23. A composition comprising the reagent of any one of claims 1-22 and a pharmaceutically acceptable excipient.
- **24**. A method for detecting esophageal adenocarcinoma (EAC), high grade dysplasia (HGD) of the esophagus, or Barrett's neoplasia in a patient comprising the steps of administering the reagent of any one of claims **1-22** to the patient and detecting binding of the reagent to esophageal cells of the patient.
- 25. A method of determining the effectiveness of a treatment for esophageal adenocarcinoma (EAC), high grade dysplasia (HGD) of the esophagus, or Barrett's neoplasia in a patient comprising the step of administering the reagent of any one of claims 1-22 to the patient, visualizing a first amount of cells labeled with the reagent, and comparing the

first amount to a previously-visualized second amount of cells labeled with the reagent,

- wherein a decrease in the first amount cells labeled relative to the previously-visualized second amount of cells labeled is indicative of effective treatment.
- **26**. The method of claim **24**, further comprising obtaining a biopsy of the cells labeled by the reagent.
- 27. A method for delivering a therapeutic moiety to esophageal adenocarcinoma (EAC) cells, high grade dysplatic (HGD) cells of the esophagus, or Barrett's neoplastic cells of a patient comprising the step of administering the reagent of any one of claims 1-22 to the patient.
- 28. A kit comprising the composition of claim 23 and instructions for use of the composition in a patient or cells of a patient.
- 29. The kit of claim 28, further comprising a device for administering the composition to the patient or to the cells of the patient.

\* \* \* \* \*